Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus?
暂无分享,去创建一个
M. Petri | M Petri | C H To | C. To | Michelle Petri
[1] M. Tikly,et al. Autoantibodies in black South Africans with systemic lupus erythematosus: Spectrum and clinical associations , 2005, Clinical Rheumatology.
[2] J. Mikdashi,et al. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. , 2004, Rheumatology.
[3] G. Ruiz-Irastorza,et al. Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus , 2004, Lupus.
[4] D. Isenberg,et al. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus , 2004, Annals of the rheumatic diseases.
[5] C. Lau,et al. Damage accrual in southern Chinese patients with systemic lupus erythematosus. , 2003, The Journal of rheumatology.
[6] C. Gordon,et al. Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. , 2003, Rheumatology.
[7] L. Magder,et al. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. , 2002, The Journal of rheumatology.
[8] L. Magder,et al. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. , 2001, Arthritis and rheumatism.
[9] D. Alarcón-Segovia,et al. Long-term prognosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. , 2000, Journal of autoimmunity.
[10] L. Magder,et al. Damage in systemic lupus erythematosus and its association with corticosteroids. , 2000, Arthritis and rheumatism.
[11] N. Bianco,et al. Cluster analysis of antinuclear autoantibodies in the prognosis of SLE nephropathy: are anti-extractable nuclear antibodies protective? , 2000, Lupus.
[12] J. Ioannidis,et al. Risk factors for central nervous system involvement in systemic lupus erythematosus. , 2000, QJM : monthly journal of the Association of Physicians.
[13] J. Ioannidis,et al. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. , 2000, The American journal of medicine.
[14] C. Gordon,et al. The association of socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus. , 1999, Rheumatology.
[15] W A Wilson,et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. , 1999, Arthritis and rheumatism.
[16] Caroline Gordon,et al. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. , 1999, Arthritis and rheumatism.
[17] F. Medina,et al. Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration , 1998, Lupus.
[18] D. Isenberg,et al. Long-term follow-up of autoantibody profiles in black female lupus patients and clinical comparison with Caucasian and Asian patients. , 1997, British journal of rheumatology.
[19] S. Gutierrez-Ureña,et al. Autoantibody profile in African-American patients with lupus nephritis , 1996, Lupus.
[20] D. Symmons,et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. , 1996, Arthritis and rheumatism.
[21] G. Hughes,et al. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. , 1995, The American journal of medicine.
[22] I. Scharrer,et al. Criteria for the Diagnosis of Lupus Anticoagulants: An Update , 1995, Thrombosis and Haemostasis.
[23] P. Limburg,et al. Prevention of relapses in systemic lupus erythematosus , 1995, The Lancet.
[24] M. Petri,et al. One Hundred Anti‐Ro (SS‐A) Antibody Positive Patients: A 10‐Year Follow‐Up , 1995, Medicine.
[25] S. Studenski,et al. Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes. , 1995, Arthritis and rheumatism.
[26] J. Nossent,et al. Course and prognostic value of Systemic Lupus Erythematosus Disease Activity Index in black Caribbean patients. , 1993, Seminars in arthritis and rheumatism.
[27] G. Hughes,et al. Systemic Lupus Erythematosus: Clinical and Immunologic Patterns of Disease Expression in a Cohort of 1,000 Patients , 1993 .
[28] M. Okamura,et al. Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology. , 1993, Annals of the rheumatic diseases.
[29] M. Petri,et al. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. , 1991 .
[30] C. Kallenberg,et al. Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus. , 1990, Seminars in arthritis and rheumatism.
[31] P. Limburg,et al. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. , 1990, Arthritis and rheumatism.
[32] S. Studenski,et al. Clinical manifestations of systemic lupus erythematosus. Identification of racial and socioeconomic influences. , 1990, Archives of internal medicine.
[33] G. Hughes,et al. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. , 1989, The American journal of medicine.
[34] J F Fries,et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.